Cetrorelix is a decapeptide GnRH (LHRH) antagonist: unlike agonists it suppresses LH and FSH at once, without an initial surge, by competitive receptor blockade; after phase III trials in IVF it became the first LHRH antagonist approved for clinical use.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Cetrorelix is a decapeptide GnRH (LHRH) antagonist: unlike agonists it suppresses LH and FSH at once, without an initial surge, by competitive receptor blockade; after phase III trials in IVF it became the first LHRH antagonist approved for clinical use. · pmid:10972520
In 65 women undergoing ovarian stimulation for IVF, a single 3 mg or 2 mg injection of cetrorelix prevented LH surges for at least three days. · pmid:9806259
CAS registry number 120287-85-6, 130143-01-0. · pubchem:25074887
Where the evidence actually sits
Established50%
Emerging50%
Proportion of the 2 claims about Cetrorelix standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cetrorelix yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
The LHRH antagonist cetrorelix: a review. · pmid 10972520 · 2000
Observational evidence· resolved human data at the emerging tier: thin, or contested
The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. · pmid 9806259 · 1998
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.